GlassScriptPhysician profile
Matthew A Ramsey
NPI 1699261099
$5,350.91
in general payments reported to CMS, 2019-2025
37 companies · $1,887 in 2025
The $1,887 reported for 2025 was more than what 93% of Adult Health (Nurse Practitioner) providers received nationally (typical 2025 total: $182).
See the full distribution for Adult Health (Nurse Practitioner)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $407 · 2022: $598 · 2023: $932 · 2024: $1,526 · 2025: $1,887.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,345.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,345.47 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $1,009.08 | 2021-2025 | |
| Alexion Pharmaceuticals, INC. | $601.75 | 2021-2024 | Ultomiris, Soliris |
| Biogen, INC. | $467.38 | 2023-2025 | Vumerity, Tysabri, Skyclarys |
| Ucb, INC. | $408.73 | 2023-2025 | Rystiggo, Zilbrysq, Briviact |
| Argenx US, INC. | $351.60 | 2022-2025 | Vyvgart Hytrulo, Vyvgart |
| Eisai INC. | $326.39 | 2023-2025 | |
| Sk Life Science, INC. | $292.09 | 2022-2025 | |
| Teva Pharmaceuticals USA, INC. | $250.52 | 2022-2025 | Ajovy, Austedo Xr, Austedo Xr |
| Lundbeck LLC | $210.18 | 2023-2025 | Vyepti |
| Otsuka America Pharmaceutical, INC. | $130.31 | 2024-2025 | Rexulti |
| Abbvie INC. | $125.40 | 2021-2025 | |
| Smith+Nephew, INC. | $117.80 | 2021 | |
| Neurocrine Biosciences, INC. | $116.03 | 2023-2025 | Ingrezza, Ongentys |
| Sunovion Pharmaceuticals INC. | $110.44 | 2021-2022 | |
| Genentech USA, INC. | $106.52 | 2023-2025 | Ocrevus Zunovo, Ocrevus, Enspryng |
Show all 37 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Integra Lifesciences Corporation | $68.17 | 2024 | Integra, Primatrix, Integra Dermal Regeneration Template |
| Tg Therapeutics, INC. | $61.29 | 2025 | |
| Amgen INC. | $57.71 | 2021-2022 | |
| Acadia Pharmaceuticals INC | $50.84 | 2025 | Nuplazid |
| Astrazeneca Pharmaceuticals LP | $50.62 | 2024 | Andexxa |
| Csl Behring | $43.48 | 2025 | Hizentra |
| Nuvasive, INC. | $36.75 | 2021 | |
| Pfizer INC. | $36.07 | 2025 | |
| Lilly USA, LLC | $35.38 | 2021-2022 | |
| Nevro Corp. | $33.84 | 2023 | Senza |
| Tanabe Pharma America, INC. | $27.96 | 2021-2022 | |
| Alnylam Pharmaceuticals INC. | $25.45 | 2022 | |
| Janssen Pharmaceuticals, INC | $24.81 | 2021-2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $24.71 | 2023 | |
| Axsome Therapeutics, INC. | $22.40 | 2025 | Symbravo |
| Grt US Holding, INC. | $22.18 | 2021 | |
| Neurelis, INC. | $20.21 | 2025 | Valtoco |
| Avion Pharmaceuticals | $19.43 | 2022 | |
| Adamas Pharmaceuticals, INC. | $19.26 | 2021 | |
| Harmony Biosciences LLC | $18.71 | 2025 | |
| Amneal Pharmaceuticals LLC | $14.58 | 2022 | |
| Avanir Pharmaceuticals, INC. | $12.84 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Matthew Ramsey listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.